Revolution Medicines’ RASONQUE has become the first broad RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma after Phase 3 data showed a 60% reduction in the risk of death compared with chemotherapy. The approval matters well beyond one cancer because it tests whether RAS, long regarded as one of oncology’s hardest targets, can support an entire
Revolution Medicines has secured FDA approval for Rasonque, or daraxonrasib, after a 500-patient Phase 3 trial showed median survival of 13.2 months compared with 6.7 months on chemotherapy in previously treated metastatic pancreatic cancer.
Revolution Medicines’ once-daily daraxonrasib improved median overall survival to 13.2 months from 6.7 months with chemotherapy in RASolute 302, giving metastatic pancreatic adenocarcinoma its first FDA-approved broad RAS-targeted therapy.
ERAS-0015 wins FDA Fast Track status after a 57% early response signal in KRAS pancreatic cancer as Erasca prepares three registration-focused trials.
Elephas reports early elive data showing cytotoxicity measurement with daraxonrasib, expanding live tumor profiling beyond immunotherapy.
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.